Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DK3QD9
|
|||
| Drug Name |
ORIN1001
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Metastatic breast cancer [ICD-11: 2C6Y] | Phase 1/2 | [1] | |
| Company |
Orinove
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Endoplasmic reticulum to nucleus signaling 1 (ERN1) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03950570) ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Orinove. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.